

# Evaluating Conflict of Interest Policies to Promote Quality Use Of Medicines in Australian Hospitals



A Bennett<sup>1</sup>, L Parker<sup>2</sup>, E Karanges<sup>2</sup>, L Bero<sup>2</sup>
NSW Therapeutic Advisory Group<sup>1</sup>; Charles Perkins Centre, The University of Sydney<sup>2</sup>

# Background

The National Medicines Policy:

- outlines a fundamental set of principles to ensure Australians receive the best outcomes from medicines use; and,
- recognises that multiple stakeholders, e.g. clinicians, policymakers, regulators and the pharmaceutical industry, have critical roles in achieving quality use of medicines (QUM) albeit with different motivations and perspectives.

There is evidence that the pharmaceutical industry can negatively impact quality decision-making regarding medicines.



Hence various professional organisations have published conflicts of interest (CoI) policies to manage bias in decision-making.

## **Project objectives**

- 1. Develop gold standard criteria for determining CoI for individual and institutional activities relevant to hospitals' medicines use.
- 2. Undertake a scoping study to evaluate the current rigour of existing Col policies or guidelines against the gold standard criteria.

### Action

No universal gold standard to govern interactions between the pharmaceutical industry and health professionals exists.

27 gold standard criteria under various categories were developed following a review of professional organisation recommendations (Table 1). A scoring system to assess level of restriction was created (Table 2).

### Results

Table 1: Gold Standard Criteria to evaluate Col policies # applies to institutions; \* applies to individuals

Category	Criteria	Category	Criteria
	Payment 1. Industry sponsored research# 2. Ex-gratia payments & special purpose accounts# 3. Sponsored positions#		17. Drug samples/started packs <sup>#</sup> 18. Medicine Access Programs incl Product Familiarisation Programs <sup>‡</sup>
· · · · · · · · · · · · · · · · · · ·		Company representatives	19. Industry reps attending public hospitals/health services#
	0 Funding 9, nayments not otherwise specified	Enforcement	Advertising  20. Promotion & promotional displays# 21.Banning the promotion of antimicrobials & other specific medicines#  22. Conflict of interest disclosure requirement# 23. Clinical private practice disclosure requirement# 24. Outside employment disclosure requirement# 25. Breach of guideline#
	<ul> <li>11. Sponsored meeting/conference events</li> <li>12. Continuing medical education sponsorship</li> <li>13. Travel/ accommodation/ entertainment sponsorship*</li> <li>14. Payment of conference registration*</li> </ul>	000000	
Gifts	15. Gifts (anatomical models, books etc) **	Education (proactive)	26. Encouraging the creation of independent learning#
eals & refreshments	16. Institutional e.g. grand rounds & individual e.g. morning coffees		27. Education regarding potential for industry influence associated with industry funding or various activities e.g. research, events#

Table 2: Scoring system according to level of restriction

Level of restriction	Score	Notes	
Prohibited	3	Strictly prohibited	
Strong restriction	2	Detailed Col management strategies	
Weak restriction	1	Only declaration required & no specific management mentioned	
No restriction	0	Activity is allowed	
		<u>-</u>	

# Review of existing Col policies 12 identified (A cross-sectional search of significant Australian stakeholders of hospital QUM via website search & direct contact) 6 jurisdictional health departments & hospital groups advisory bodies No private hospital groups advisory bodies

Figure 1: Scatter plot to compare restriction score and % coverage of policies, n=12





Figure 2: Comparison of enforcement levels in organisational Col policies for criteria 22-27, n= 11 \*Organisations could either score 0 (no mention) or 1 (activities mentioned).



# Conclusions

- The Gold Standard criteria and scoring system effectively evaluated CoI policies.
- They can be used by stakeholders to determine the rigour of their policies & assist development of consensus about Col management across all stakeholders.
- The policies of professional societies tended to have lower criteria coverage & lower restriction scores. The policies of the AMA, SHPA and Pharmacy Board of Australia had limited information and focused on relationships between health professionals and patients rather than health professionals and industry.
- The RACP policy is the most recent and provides support to physicians to identify, assess and manage Col.
- Jurisdictional policies had greater rigour but their readability varied.
- The Tasmanian policy was the most comprehensive while the South Australian document was most readable with an accompanying fact sheet.
- It was sometimes difficult to access policies without direct requests. No private hospital group provided CoI policies despite requests.
- Many policies incorrectly suggested disclosure of CoI is an adequate management strategy. Many policies also did not provide specific disclosing pathways, rules or forms.